Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalInfectious DiseaseMalariaTrial Update

Study on Malaria Infection Factors in Pregnant Women and Children in Mali

This study is critical as it aims to uncover factors influencing malaria susceptibility in vulnerable populations, which could significantly inform vaccine development. Insights gained may lead to improved public health strategies and interventions targeting malaria in pregnant women and young children.

Published: June 23, 2026
Updated: June 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Infectious Disease / Malaria
Asset: Study
Trial SummaryCLN

Phase III

Infectious Disease / Malaria

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This study is critical as it aims to uncover factors influencing malaria susceptibility in vulnerable populations, which could significantly inform vaccine development. Insights gained may lead to improved public health strategies and interventions targeting malaria in pregnant women and young children.

Why it matters

This study is critical as it aims to uncover factors influencing malaria susceptibility in vulnerable populations, which could significantly inform vaccine development. Insights gained may lead to improved public health strategies and interventions targeting malaria in pregnant women and young children.

What changed

Trial Update

Analysis

A longitudinal study will enroll up to 2000 pregnant women and their infants, and 2000 children aged 0-3 years to investigate malaria susceptibility.

This study is critical as it aims to uncover factors influencing malaria susceptibility in vulnerable populations, which could significantly inform vaccine development. Insights gained may lead to improved public health strategies and interventions targeting malaria in pregnant women and young children.

Monitor results from the study regarding immunologic responses and the impact of pregnancy malaria on childhood outcomes.

Related companies & assets

Assets

  • Study →
  • malaria vaccine developers →

Sources & Humanexa intelligence

Source links

  • Study on Malaria Infection Factors in Pregnant Women and Children in Mali ↗

Related Humanexa pages

  • Study on Malaria Infection Factors in Pregnant Women and Children in Mali →

Related signals

Trial SummaryCLN

Phase III

Respiratory / COPD

Status

Active

Signal Score

8.2

Clinicalhigh signal

CHARM-COPD Program Evaluates Post-Discharge Care for COPD Patients

The CHARM-COPD program aims to assess the feasibility and acceptability of a care program for COPD patients post-discharge.

June 24, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / Non-small Cell Lung Cancer

Status

Initiated

Sponsor

Merck

Signal Score

8.4

Clinicalhigh signal

Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna

A clinical trial is underway to evaluate the efficacy of intismeran autogene combined with pembrolizumab in NSCLC patients.

June 24, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.